ATE552856T1 - Selektive norepinephrin-serotonin- wiederaufnahmehemmer zur behandlung des fibromyalgie-syndroms, des chronischen müdigkeitssyndroms und von schmerzen - Google Patents

Selektive norepinephrin-serotonin- wiederaufnahmehemmer zur behandlung des fibromyalgie-syndroms, des chronischen müdigkeitssyndroms und von schmerzen

Info

Publication number
ATE552856T1
ATE552856T1 AT02793880T AT02793880T ATE552856T1 AT E552856 T1 ATE552856 T1 AT E552856T1 AT 02793880 T AT02793880 T AT 02793880T AT 02793880 T AT02793880 T AT 02793880T AT E552856 T1 ATE552856 T1 AT E552856T1
Authority
AT
Austria
Prior art keywords
syndrome
chronic fatigue
pain
fatigue syndrome
reuppost
Prior art date
Application number
AT02793880T
Other languages
English (en)
Inventor
Srinivas Rao
Jay Kranzler
Original Assignee
Cypress Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cypress Bioscience Inc filed Critical Cypress Bioscience Inc
Application granted granted Critical
Publication of ATE552856T1 publication Critical patent/ATE552856T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02793880T 2001-11-05 2002-11-05 Selektive norepinephrin-serotonin- wiederaufnahmehemmer zur behandlung des fibromyalgie-syndroms, des chronischen müdigkeitssyndroms und von schmerzen ATE552856T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/014,149 US6635675B2 (en) 2001-11-05 2001-11-05 Method of treating chronic fatigue syndrome
PCT/US2002/035396 WO2003039598A1 (en) 2001-11-05 2002-11-05 Selective norepinephrine serotonin reuptake inhibitors for treating fibromyalgia syndrome, chronic fatique syndrome and pain

Publications (1)

Publication Number Publication Date
ATE552856T1 true ATE552856T1 (de) 2012-04-15

Family

ID=21763814

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02793880T ATE552856T1 (de) 2001-11-05 2002-11-05 Selektive norepinephrin-serotonin- wiederaufnahmehemmer zur behandlung des fibromyalgie-syndroms, des chronischen müdigkeitssyndroms und von schmerzen

Country Status (7)

Country Link
US (1) US6635675B2 (de)
EP (2) EP1463528B1 (de)
AT (1) ATE552856T1 (de)
CA (1) CA2467356C (de)
ES (2) ES2433080T3 (de)
PT (2) PT1463528E (de)
WO (1) WO2003039598A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070117869A1 (en) * 2000-11-01 2007-05-24 Cognition Pharmaceuticals Llc Methods for treating coginitive impairment and improving cognition
WO2005000203A2 (en) * 2001-10-31 2005-01-06 Sention, Inc. Methods for treating cognitive impairment and improving cognition
US20030232890A1 (en) * 2000-11-01 2003-12-18 Sention, Inc. Methods for treating an impairment in memory consolidation
US7619005B2 (en) * 2000-11-01 2009-11-17 Cognition Pharmaceuticals Llc Methods for treating cognitive impairment in humans with Multiple Sclerosis
US20050059743A1 (en) * 2000-11-01 2005-03-17 Sention, Inc. Methods for treating mild cognitive impairment and alzheimer's disease
US20030119884A1 (en) * 2000-11-01 2003-06-26 Epstein Mel H. Methods and compositions for regulating memory consolidation
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US20040034101A1 (en) * 2001-11-05 2004-02-19 Cypress Bioscience, Inc. Treatment and prevention of depression secondary to pain (DSP)
AU2003213009A1 (en) * 2002-02-12 2003-09-04 Cypress Bioscience, Inc. Methods of treating attention deficit/hyperactivity disorder (adhd)
EP1545489A4 (de) * 2002-07-24 2006-08-23 Cypress Bioscience Inc BEHANDLUNG VON DEPRESSION ALS SEKUNDûRE FOLGEN VON SCHMERZEN (DSP)
MXPA05001705A (es) * 2002-08-14 2005-04-19 Pharmacia & Upjohn Co Llc Uso de reboxetina para el tratamiento de sofocos.
MXPA05003550A (es) * 2002-10-03 2006-01-24 Cypress Bioscience Inc Incremento de dosificacion y dosis diaria dividida de anti-depresivos para tratar padecimientos neurologicos.
US7704527B2 (en) * 2002-10-25 2010-04-27 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
MXPA05006209A (es) * 2002-12-13 2005-08-19 Warner Lambert Co Pregabalina y sus derivados para el tratamiento de fibromialgia y otros trastornos relacionados.
FR2851163B1 (fr) * 2003-02-14 2007-04-27 Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
MXPA05008652A (es) * 2003-02-14 2005-10-18 Pf Medicament Uso del enantiomero (1s,2r) de milnacipran para la preparacion de un medicamento.
RU2006107534A (ru) * 2003-09-12 2007-09-20 Уорнер-Ламберт Компани Ллс (Us) Комбинация, включающая альфа-2-дельта-лиганд анд и ssri и/или snri, для лечения депрессии и тревожного расстройства
US20050181050A1 (en) * 2004-01-28 2005-08-18 Collegium Pharmaceutical, Inc. Dosage forms using drug-loaded ion exchange resins
AU2005238296A1 (en) * 2004-04-30 2005-11-10 Warner-Lambert Company Llc Substituted morpholine compounds for the treatment of central nervous system disorders
GB0409744D0 (en) * 2004-04-30 2004-06-09 Pfizer Ltd Novel compounds
EP1846040A2 (de) * 2005-01-28 2007-10-24 Collegium Pharmaceutical, Inc. Nicht ionische und nicht wässrige transportelemente zur topischen und oralen verabreichung träger-komplexierter wirkstoffe
GEP20125566B (en) 2005-07-15 2012-07-10 Amr Technology Inc Aryl-and heteroaryl-substituded tetrahydro-benzazepines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
US7994220B2 (en) 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
WO2008009663A1 (en) * 2006-07-19 2008-01-24 Boehringer Ingelheim International Gmbh Treatment of pain
EP2114868A2 (de) * 2007-02-28 2009-11-11 Ranbaxy Laboratories Limited Neuartige polymorphe formen von milnacipran-hydrochlorid
EP2116618A1 (de) 2008-05-09 2009-11-11 Agency for Science, Technology And Research Diagnose und Behandlung des Kawasaki-Syndroms
FR2944011B1 (fr) 2009-04-03 2011-05-20 Pf Medicament Derives d'aminocyclobutane ou d'aminocyclobutene, leur procede de preparation et leur utilisation a titre de medicaments.
US20100286260A1 (en) * 2009-05-05 2010-11-11 Forest Laboratories Holdings Ltd. Milnacipran formulations
WO2010132487A1 (en) 2009-05-12 2010-11-18 Bristol-Myers Squibb Company CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF
PE20120373A1 (es) 2009-05-12 2012-05-17 Albany Molecular Res Inc 7-([1,2,4]triazolo[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina
US8865937B2 (en) * 2009-11-06 2014-10-21 Mahendra G. Dedhiya Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide
WO2012024397A2 (en) 2010-08-17 2012-02-23 Albany Molecular Research, Inc. 2,5-methano-and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
FR2978350B1 (fr) 2011-07-28 2013-11-08 Pf Medicament Medicament a base de levomilnacipran pour la rehabilitation fonctionnelle apres accident neurologique aigu

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2508035A1 (fr) 1981-06-23 1982-12-24 Fabre Sa Pierre Derives d'aryl-1-aminomethyl-2 cyclopropanes carboxamides (z), leur preparation et leur application en tant que medicaments utiles dans le traitement des troubles du systeme nerveux central
IT1188212B (it) 1985-12-20 1988-01-07 Paolo Colombo Sistema per il rilascio a velocita' controllata di sostanze attive
US4891223A (en) 1987-09-03 1990-01-02 Air Products And Chemicals, Inc. Controlled release delivery coating formulation for bioactive substances
FR2640972B1 (de) 1988-12-28 1991-04-19 Pf Medicament
IT1237904B (it) 1989-12-14 1993-06-18 Ubaldo Conte Compresse a rilascio a velocita' controllata delle sostanze attive
CA2041774C (en) 1990-11-27 1994-04-19 Mircea A. Mateescu Use of cross-linked amylose as a matrix for the slow release of biologically active compounds
US5603956A (en) 1990-11-27 1997-02-18 Labopharm Inc. Cross-linked enzymatically controlled drug release
US5326570A (en) 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
GB9215043D0 (en) 1992-07-15 1992-08-26 Flow Inc K Fluid mass flow meters
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
US5455046A (en) 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5397574A (en) 1993-10-04 1995-03-14 Andrx Pharmaceuticals, Inc. Controlled release potassium dosage form
US5399358A (en) 1993-11-12 1995-03-21 Edward Mendell Co., Inc. Sustained release formulations for 24 hour release of metroprolol
US5419917A (en) 1994-02-14 1995-05-30 Andrx Pharmaceuticals, Inc. Controlled release hydrogel formulation
EP0747348A4 (de) 1994-02-22 1999-07-07 Asahi Chemical Ind Aminoalkylcyclopropan-derivate
US5458888A (en) 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
US5458887A (en) 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
US5399359A (en) 1994-03-04 1995-03-21 Edward Mendell Co., Inc. Controlled release oxybutynin formulations
ES2270426T3 (es) 1994-03-18 2007-04-01 Supernus Pharmaceuticals, Inc. Sistema de suministros de farmacos emulsionados.
US5399362A (en) 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
US5464633A (en) 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
US6103263A (en) 1994-11-17 2000-08-15 Andrx Pharmaceuticals, Inc. Delayed pulse release hydrogel matrix tablet
US5585115A (en) 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US5567441A (en) 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
US5824638A (en) 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
EP0759299B1 (de) * 1995-08-16 2000-04-26 Eli Lilly And Company Potenzierung von Serotonin-Wirkstoffresponz
FR2746314B1 (fr) 1996-03-25 1998-06-12 Pf Medicament Produit contenant du milnacipran et de l'idazoxan comme preparation pharmaceutique combinee
AU2587297A (en) * 1996-03-25 1997-10-17 Eli Lilly And Company Method for treating pain
FR2752732B1 (fr) * 1996-08-28 1998-11-20 Pf Medicament Forme galenique a liberation prolongee de milnacipran
AU721653B2 (en) 1996-10-25 2000-07-13 Supernus Pharmaceuticals, Inc. Soluble form osmotic dose delivery system
US5837379A (en) 1997-01-31 1998-11-17 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
FR2759906B1 (fr) 1997-02-21 2004-06-04 Pf Medicament Utilisation de milnacipran et de ses derives pour la preparation d'un medicament destine au traitement de certaines maladies psychiatriques
CA2216215A1 (en) 1997-04-05 1998-10-05 Isa Odidi Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity
JP3950175B2 (ja) 1997-05-30 2007-07-25 オスモティカ・コーポレイション 多層浸透デバイス
US5885616A (en) 1997-08-18 1999-03-23 Impax Pharmaceuticals, Inc. Sustained release drug delivery system suitable for oral administration
US6096340A (en) 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US5916595A (en) 1997-12-12 1999-06-29 Andrx Pharmaceutials, Inc. HMG co-reductase inhibitor
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
AU3891299A (en) * 1998-05-21 1999-12-06 Eli Lilly And Company Combination therapy for treatment of depression
US6106862A (en) 1998-08-13 2000-08-22 Andrx Corporation Once daily analgesic tablet
US6099862A (en) 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
US6323242B1 (en) * 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
WO2000056318A1 (en) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Treatment of neuropathic pain or fibromyalgia
PT1202722E (pt) 1999-08-13 2005-11-30 L & L Technologies Llc Usos para o tratamento ou prevencao de disturbios do sono usando doses muito baixas de ciclobenzaprina
GB2355191A (en) 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
EP1353675A2 (de) * 2001-01-02 2003-10-22 PHARMACIA & UPJOHN COMPANY Neue kombination von norepinehrin reuptake hemmern und neuroleptika

Also Published As

Publication number Publication date
ES2433080T3 (es) 2013-12-09
EP2322225B1 (de) 2013-07-31
EP2322225A1 (de) 2011-05-18
EP1463528A1 (de) 2004-10-06
PT1463528E (pt) 2012-06-27
US6635675B2 (en) 2003-10-21
CA2467356C (en) 2008-06-17
PT2322225E (pt) 2013-11-07
US20030139476A1 (en) 2003-07-24
EP1463528B1 (de) 2012-04-11
WO2003039598A1 (en) 2003-05-15
WO2003039598A8 (en) 2004-06-03
ES2395462T3 (es) 2013-02-12
CA2467356A1 (en) 2003-05-15

Similar Documents

Publication Publication Date Title
ATE552856T1 (de) Selektive norepinephrin-serotonin- wiederaufnahmehemmer zur behandlung des fibromyalgie-syndroms, des chronischen müdigkeitssyndroms und von schmerzen
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
BR0116206A (pt) Peptìdeo yy e agonistas de peptìdeo yy para tratamento de distúrbios metabólicos
PL372372A1 (en) Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes
DE69905938D1 (de) Kombination von duloxetin mit nichtsteroid-entzündungshemmern für die behandlung von schmerz
DE60042598D1 (de) Medikamente zur behandlung des syndroms der chronishen ermüdung, das mit fibromyalgie und reizdarm assoziert ist.
EA200001258A1 (ru) Пирролзамещенные 2-индолиноны (варианты), фармацевтическая композиция (варианты), способ модулирования каталитической активности протеинкиназы, способ лечения или профилактики нарушения в организме, связанного с протеинкиназой
CY1112932T1 (el) Αναστολεις sμαd7 για τη θεραπευτικη αγωγη ασθενειων του κνς
EA200801805A1 (ru) Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
ATE329588T1 (de) Verwendung von sibutramin zur behandlung von von organischen störungen verursachten zns- erkrankungen
ATE301995T1 (de) Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen
HUP0202687A2 (hu) Gyorsan ható szelektív szerotonin-újrafelvételt gátlókat alkalmazó eljárások nemi működési zavarok kezelésére
ATE312608T1 (de) Cabergolin zur behandlung von fibromyalgie und chronic-fatigue-syndrom
BRPI0411864A (pt) combinação de inibidores de src quinase e agentes quimioterápicos para o tratamento de doenças proliferativas
DE602004025808D1 (de) Gaboxadol zur behandlung von depressionen und anderen affektiven störungen
DE602004021847D1 (de) Verfahren zur prävention und behandlung von diabetes mit neurturin
ATE376419T1 (de) Carbostyril-derivate mit selektiven serotonin- aufnahme inhibitoren, zur behandlung von gemütskrankheiten
BR0008603A (pt) Método para tratamento de copd
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
HUP0204551A2 (hu) Eljárás a pikkelysömör kezelésére
DE60229123D1 (de) Behandlung von fibromyalgie mit pindolol
EA200301299A1 (ru) Применение ингибиторов il-18 для лечения и предотвращения повреждений цнс
MY130725A (en) Composition and method for treating allergic diseases
DE60236927D1 (de) Suchtpraevention in der schmerzbehandlung mit gamma vinyl gaba
ATE536874T1 (de) Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen